Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 16/20 | 0.78 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.70 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.70 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25006485 | 0.98 | GRIN2B (0.76) | GRIN2BSIGMAR1GRIN1 | |
| SCHEMBL2661158 | 0.92 | GRIN2B (0.68) | GRIN2BSIGMAR1GRIN1OPRM1OPRL1 | |
| SCHEMBL2661157 | 0.92 | GRIN2B (0.68) | GRIN2BSIGMAR1GRIN1OPRM1OPRL1 | |
| SCHEMBL23599404 | 0.90 | GRIN2B (0.69) | GRIN2BSIGMAR1GRIN1 | |
| SCHEMBL21242573 | 0.90 | GRIN2B (0.69) | GRIN2BSIGMAR1GRIN1 | |
| SCHEMBL23019750 | 0.90 | GRIN2B (0.69) | GRIN2BSIGMAR1GRIN1 | |
| SCHEMBL14117439 | 0.86 | GRIN2B (0.67) | GRIN2BSIGMAR1GRIN1OPRM1OPRL1 | |
| SCHEMBL662411 | 0.86 | GRIN2B (0.76) | GRIN2BSIGMAR1GRIN1OPRM1OPRL1 | |
| SCHEMBL27929338 | 0.85 | GRIN2B (0.71) | GRIN2BSIGMAR1GRIN1OPRM1OPRL1 | |
| SCHEMBL5689576 | 0.84 | GRIN2B (0.65) | GRIN2BSIGMAR1GRIN1OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312542-A1 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-05 | — | — | US | disclosed |
| US-20230312542-A1 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-05 | — | — | US | disclosed |
| US-20230312542-A1 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-05 | — | — | US | disclosed |
| EP-4129402-A1 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2023-02-08 | — | — | EP | disclosed |
| EP-4129402-A1 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2023-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312542-A1 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | VHL, MDM2, NEDD4 | GRIN2B 3758/4885SIGMAR1 2478/4885GRIN1 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.